Drug intelligence / Profile preview

Forza

Development stage
Unknown
Lead developer
Eli Lilly
Modality
Recombinant Proteins and Enzymes, Peptides, Small Molecules
Administration
Subcutaneous, Oral
01

Overview

"Forza" is a non-specific trade name associated with several distinct pharmaceutical, veterinary, and nutraceutical products across international markets. In the context of biotechnology and human medicine, it primarily serves as a brand name for **teriparatide** (a recombinant human parathyroid hormone fragment PTH 1-34) used as an anabolic agent to treat osteoporosis, and **tadalafil** (a PDE5 inhibitor) used for erectile dysfunction and pulmonary arterial hypertension. Teriparatide, originally developed by Eli Lilly and marketed as Forza by Laboratorios Raffo, acts as an agonist at the Parathyroid Hormone Receptor 1 (PTH1R) to stimulate bone formation. Tadalafil, marketed as Forza by Lloyd Laboratories, increases cGMP levels to facilitate smooth muscle relaxation. Additionally, the name "Forza" is used for **nitenpyram**, a neonicotinoid insecticide marketed by Zydus for veterinary flea control, and **tenofovir disoproxil fumarate**, an antiretroviral used for HIV and Hepatitis B. In the United Kingdom, FORZA is also a prominent brand of dietary weight-loss supplements containing ingredients such as caffeine and acetyl-L-carnitine.

Brand names
ForzaForteoForsteoTeriboneCialisVireadCapstar
Other names
teriparatidetadalafilnitenpyramtenofovir disoproxil fumaraterhPTH(1-34)parathyroid hormone (1-34)
02

Targets

PDE5 (Phosphodiesterase 5A)Human immunodeficiency virus type 1 reverse transcriptasePTH1R (Parathyroid hormone/Parathyroid hormone-related peptide receptor type 1)Nicotinic Acetylcholine Receptor

Beyond the preview

Go deeper on Forza.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Forza.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call